

A Tasty Twist: Exploring the Potential of Edible Vaccines

Vrushali Mohan Murari

Bachelor of Pharmacy, Dr. Shivajirao Kadam College of Pharmacy Kasabe Dirgraj Sangli.

Abstract:

A biological preparation known as a vaccine offers active acquired immunity to a specific infectious or malignant disease. There are various vaccine varieties, such as: inactivated vaccines. live-attenuated immunizations. mRNA (messenger RNA) vaccines. vaccinations include subunits, recombinants, polysaccharides, and conjugates. Genetically engineered crops with antigens for particular diseases are known as edible vaccines. Due to the vaccine's simplicity of culture, this lowers the product cost. Since they don't require adjuvants that strengthen the susceptible response, edible vaccines are a viable method of immunization delivery. In terms of vacuity, storage, medication, product, and transportation, edible vaccines are also economical. Foods under such operation include potato, banana, lettuce, soybean, rice, lettuce, apple, peas, soyabean, cherry tomatoes, alfalfa, tomatoes, carrot etc. This review focuses on the development of edible vaccines over the years and the various lookouts it holds as technology keeps developing. The evolution of vaccines has led to the discovery of new forms of vaccination that are efficacious and cover a broad array of disease.

Keywords: Edible Vaccines, Diseases, Mucosal Immune System.

Introduction:

Vaccine is a natural medication intended to produce impunity to a complaint by stimulating the product of antibodies. Comestible vaccines are called by several indispensable names similar as food vaccines, oral vaccines, subunit vaccines, and green vaccines. they feel to be a feasible volition especially for the poor and developing countries. the earliest vaccine to be developed was small spell vaccine by Edward Jenner in 1796 and the work was afterward continued by Louis Pasteur [1]. In common, the product of vaccines comprises of four main way including propagation, insulation, sanctification, and expression. further than one million people die each time of contagious conditions. Pathogens infecting the mammalian host's mucosal membrane account for 50% of these diseases [2].

Types Of Vaccines:


- Live-attenuated vaccines: these are considered the original and 1st vaccines. Here, the weakened form of a live infectious organism is used as a vaccine.
- Inactivated vaccines: These are vaccines produced using the debris of a deceased organism.
- Toxoid vaccines: The toxin produced by the organism is employed as a vaccine. Toxoid vaccines focus on preventing the negative symptoms of infection rather than the infection itself.
- Biosynthetic vaccines: As the name implies, these vaccines are man-made and closely resemble the infectious organism in structure and features.

- DNA vaccines: plasmid DNA with antigen encoding sequences. This plasmid DNA is then sent especially to a particular muscle or tissue, where it is expressed.
- Recombinant vaccines: vaccines in which bacteria express a recombinant plasmid containing the antigen-encoding gene. This protein is then purified for use as a vaccine.
- Edible vaccines: The edible portion of a plant is genetically modified to express antigens, prompting an immunological reaction when consumed.

Immunization is a global health and development success story, saving millions of lives every year. Vaccines strengthen your body's defences against infection, which reduces your chance of getting sick. The immunization causes your immune system to respond. People of all ages can now live longer, healthier lives thanks to immunizations against over 20 dangerous illnesses. Currently, immunization prevents between 3.5 and 5 million deaths per year from diseases including measles, tetanus, diphtheria, and pertussis. Immunization is a crucial component of primary healthcare and an indisputable human right. It's also one of the best financial investments you can make in your health.

Plants Which Can Be Used for Edible Vaccines:

Because vaccine antigens are heat-sensitive, plants utilized to create oral vaccines should yield edible components that may be eaten raw [3]. Furthermore, it is mandatory to be high in protein, the reason is vaccine protein makes up about 0.01–2.0 percent of a plant's overall protein composition. It should be able to be genetically altered, grow broadly, and not produce any harmful byproducts. Edible vaccines can be prepared from a variety of plants, including rice, lettuce, bananas, potatoes, tomatoes, tobacco, rice, and papayas, to prevent a range of human diseases, including cholera, measles, anthrax, and diarrhoea.



Banana:




Banana vaccinations are used to treat Hepatitis B [4]. A ubiquitous fruit, the banana, is currently being

explored as an implied container for immunizations against deadly and all-too-familiar diseases. Bananas have the advantage of being able to be ingested raw, as opposed to potatoes or rice, which must be cooked, and they can also be consumed pure [5]. Similarly, bananas are popular among children, and the plants thrive in tropical places where immunizations are most needed. As a result, the research is leaning toward using bananas as the vector because many third-world countries, who would benefit the most from edible vaccines, have tropical temperatures.

On the flip side, a new crop of banana plants takes approximately 12 months to produce fruit. Following fruiting, the plants are pruned down and a new crop of vaccine-bearing stores is planted. A new crop of vaccine-producing plants must be planted after the plants have been harvested. Furthermore, scientists have developed bananas that contain an HBV vaccine. The current injectable immunization costs \$125 each dosage, whereas the vaccine made from banana expected to cost roughly two cents per dose.


Mechanism of Action of Banana Vaccines :

Recombinant DNA Approaches for Vaccine Production and Transgenic Plants with Edible Vaccines



Considering the mucosal immune system is one of the primary conduits of pathogen invasion, edible vaccines are formulated with this in mind. The mucosal immune system, which lines the digestive tract, the airway, and genital systems, is the body's main line of resistance against most diseases. When M-cells perceive an antigen, a mucosal immune response develops. These cells can only be found in the mucosal layers of lymphoid tissues such as Peyer's patches, which are rare. The antigen enters the M-cells and moves forward to the lower area, where it is swallowed by antigen-presenting cells. The antigenic epitope on the cell surface of antigen-presenting cells can be detected by TH cells, which stimulates B cells. During the passage to the lymph node area, these B cells evolve into plasma cells and emigrate to the epithelial cells of the mucosal surface, where they generate Immuno-Banana, an edible hepatitis-B vaccine. The pathogenic virus which is harming is destroyed by the secreted IgA, by attacking a specific antigenic epitope. The memory cells in circulation tackle pathogens and induce a defence against infection the next time the virus infects the person being treated [6].


Potato:



Potatoes, a starchy root vegetable native to the Americas, are a mainstay of many foods around the world. Potatoes are tubers from the perennial plant *Solanum tuberosum*, which is a member of the nightshade family Solanaceae.

Another feasible possibility that appears to be the intended vector is genetically modified potatoes. Potato plants were used to make many of the earliest vaccinations that could be eaten. For the purpose of developing vaccinations against the Norwalk virus, hepatitis B, tetanus, and diphtheria, potatoes are a suitable model. Additionally, potatoes may help enhance the hepatitis B vaccine in humans orally [7]. Potatoes are fairly cheap tubers that are widely consumed around the world. Optimal techniques are now possible due to the abundance of data on generic modification that is available [8]. One major drawback is that cooking causes antigens to lose their natural form; therefore, refrigerators are not necessary for storage [9,10].

Potato edible vaccines primarily work by inducing systemic and mucosal immune responses in opposition to an alien pathogen.




Tomato:



The tomato, also referred to as the tomato plant (/təmeɪtoʊ/ or /təma\toʊ/), is an edible berry that is produced by the Solanum Lycopersicon plant. The species first came to be known in Mexico, Central America, and western South America.

Tomatoes are a great option because they are fast to grow and are simple to modify genetically. They can also be eaten uncooked and are tasty. The tomatoes aren't an excellent crop in the regions where edible vaccines are most desperately required, but engineered tomatoes can be preserved or processed into a paste form to assist with disseminate the vaccine. Tomatoes preserve therapeutic properties although being heat-resistant and consumable, as opposed to other plants with transgenic genes which contain protein in them. They are consequently a great replacement for HIV prevention.



Edible Tomato Vaccines in Malaria:

The disease known as malaria, which is brought on by Plasmodium protozoan parasites, is one of the greatest threats to humanity [11]. There are more than two billion people living in malaria endemic areas, and 300–500 million people contract the disease each year. Approximately 3,000,000 individuals die from malarial disease annually, with over a million of the fatalities happening among children around the age of five. The proliferation of drug-resistant parasite strains, the failure of health systems in many impacted areas, the interaction between the illness and transmission of HIV, and possibly the consequences of the changing climate are all contributing elements to an upsurge in malaria fatalities [12,13,14,15,16].

Theoretically, distinct transgenic plants expressing distinct antigenic types were used to produce the edible vaccines against malaria in transgenic tomato plants. Vaccinating individuals against two to three antigens as well as each phase of the multistage parasite development cycle would be a cost-effective, safe, and efficient technique of immunization. Differently sized, shaped, and coloured tomatoes that carry distinct antigens would enable laypeople to easily identify the immunizations.

A prominent option for use as an edible vaccination is the tomato, a plant with many uses. Due of its tasty nature and rapid growth, its customer base is wider. The main drawback of tomatoes is their quick deterioration after ripening [17].


Rice:



Almost fifty percent of the globe's population, especially across Asia and Africa, relies on rice, a cereal grain, for its primary source of sustenance. Rice is the seed of the grass species *Oryza sativa*, typically referred to as Asian rice, or, more rarely, *O. glaberrima*, sometimes known as African rice. Rice from Asia evolved into domestication between 13,500 and 8,200 years ago in China, but rice from Africa was introduced approximately 3,000 years ago. Rice has been a mainstay in many countries around the world, producing 787 million tons in 2021, ranking fourth behind sugarcane, maize, and wheat. Only around 8% of rice is traded internationally. The top three rice-consuming countries are China, India, and Indonesia.

Rice is an additional variety of plant used for the production of edible vaccinations. The advantages against other plant species included high antigen expression and extensive use in infant feeding. However, it develops slowly and requires a glasshouse climate. A 2007 study on transgenic rice (*Oryza sativa*) found a significant level of antibodies against *E. Coli*. In 2008, it was confirmed that HBsAg is functional in rice seeds. In locations where rice is the predominant food supply, plant-based vaccinations will have a huge public health impact.

Maize and rice Cereals such as rice and maize are staples in many nations. The primary factor making rice and maize appealing as potential food vaccination candidates is their extended shelf life when stored without refrigeration. However, one drawback of grains is that their growth necessitates ideal conditions and lengthy growing times [18].



The researchers Gu et al. [18] used transgenic rice to produce the recombinant protein UreB from *Helicobacter pylori*. *Helicobacter pylori*, a stomach infection, is the major cause of gastritis, ulcers of the stomach, and stomach cancer [19, 20]. *H. pylori* is a bacteria that colonizes the stomach due to its urease activity, which reduces stomach acidity [21]. Some researchers successfully vaccinated against UreB, which is predicted to be a new target for treating *H. pylori* infections [22,23,24]. They employed *Agrobacterium*-mediated transformation to deliver recombinant UreB into transgenic rice [25]. Matsumoto et al. [26] described an innovative rice-based vaccination against parasitic ailments, specifically a roundworm called *Ascaris suum*.

In order to evaluate MucoRice-CTB's immunogenicity, oral vaccination studies were first carried out on mice. Mice administered orally with MucoRice-CTB developed CTB-specific blood IgG and fecal IgA antibodies, suggesting that the vaccine could trigger both systemic and mucosal immune responses. Serum samples were subjected to an elongation experiment with Chinese rat ovarian (CHO) cells [27] and the widely utilized GM1-ELISA [28] to confirm the CT-neutralizing capacity of the IgG serum antibody following MucoRice-CTB immunization. Serum samples coupled with CT have been incubated on GM1-coated plates for GM1-ELISA analysis, which was then carried out with an anti-CTB antibody and ELISA.

Serum from mice orally administered contaminated with MucoRice-CTB reduced CT attaching to GM1, which is ganglioside, as measured by GM1-ELISA. The mice's blood antibodies efficiently neutralized CT, as seen by the absence of morphological modifications to CHO cells that were stimulated with CT after being produced with serum from mice given an oral vaccination with MucoRice-CTB, determined by the CHO elongation assay. Aside from the aforementioned in vitro experiments, an in-vivo investigation found that mice put with MucoRice-CTB showed no clinical signs of diarrhoea when challenged with CT orally. The findings also revealed that intestinal IgA antibodies generated by oral MucoRice-CTB have CT-neutralizing capabilities.

Tobacco:



In 1990, tobacco was utilized to generate the first edible vaccine. Tobacco in the Solanaceae family denotes to a category of plants in the botanical name *Nicotiana*, and it also includes any product obtained from their processed leaves. Although there are over 70 species of tobacco, *N. tabacum* is the most important commercial variant. In some countries, the stronger variety *N. rustica* is also used.


Tobacco was a previously operational model plant. It grows swiftly, generates a large number of seedlings per generation after generation, and is everlasting, among its many advantages. Tobacco has been widely used as an edible vaccine candidate [29].

Tobacco was utilized in 1990 to generate the first edible immunization, and 0.02 percent of all the total amount of soluble leaf proteins contained recombinant protein, a *Streptococcus* surface protein. It first appeared as an International Patent Cooperation Treaty-published patent application.

The tobacco plant is a hardy perennial herb that grows upright and is native to America. It comes in over 70 variants with varying biological activities. *Nicotiana benthamiana*'s principal chemical components are nitrate, sorbitol, anabasine, myosin, anatabine, nicotine, Nor nicotine, nicotinic acid, nicotelline, and nicotianine [30].

According to the World Health Organization, more than 8 million people die each year as a result of tobacco use, with over 7 million directly attributable to the consumption of tobacco as well as 1.2 million caused by the act of passive smoking (breathing in other people's tobacco smoke) [30,31,32].

The basic procedure of creating TBV comprises inserting transgenes into tobacco leaf plant cells through nuclear or plastid fusion. The antigen being targeted was given to the expression system after combining with the vector. Transgenes can be temporary or irreversible conversion systems, depending on where they are put within the plant cell [33,34].



The foreign gene is absorbed within the DNA of the cell, either in the chloroplast or nucleus, permanently modifying the genetic line and allowing it to be duplicated sexually or vegetatively [35]. Many transformation strategies can be used, including glass beads, polyethylene glycol (PEG), electroporation, micro projection, particulate bombardment, and *Agrobacterium*-mediated conversion.

Agrobacterium-mediated transformation is particularly attractive because it allows the production of multicomponent vaccines [35,36].


Dengue, a tropical endemic illness carried by the mosquitoes *Aedes aegypti* and *Aedes albopictus* [37], is caused by one of four dengue virus variants (DENV-1 to DENV-4). Dengvaxia as a trivalent in nature. live-attenuated vaccine, was recently proved to be efficacious and is now readily accessible on sale [38]. Normally, sickness prevention is achieved through appropriate vector control techniques. Tobacco, lettuce leaves, rice, and potatoes have been found in studies to be promising substrates for dengue antibody and vaccine synthesis [39]. Tobacco produces more recombinant proteins, including envelope protein region III (cEDIII) and unstructured protein 1 (NS1), which is generated from DENV-2 and has lesser specificity but higher sensitivity (40Both of them were found to produce robust immunological responses in mice. To improve the mice's oral tolerance, cEDIII has been combined with CTB, because it has a greater specificity for GM1 Ganglioside [40,41,42].

Lettuce:

The annual plant lettuce (*Lactuca sativa*) belongs to the Asteraceae family. It is mostly grown for its leaves, but it is occasionally grown for its seeds and stem. Salads are the most common application for lettuce, although it can also be grilled or used in soups, sandwiches, and wraps. Cultivated asparagus lettuce, or celtuce, is grown for its edible stems, which can be consumed fresh or cooked. After millennia of human consumption, it has gained religious and medicinal significance in addition to its original use as a leafy green. Initially, North America and Europe dominated the lettuce market, but by the late twentieth century, lettuce consumption had spread worldwide.

One of the most significant edible plants in the world is lettuce. Currently, lettuce is a potential plant that could harbour a foreign gene that would immunize humans. The *Vibrio cholerae* toxin B subunits (CTB) are potential vaccine antigens. The result of this approach was the expression of the CTB, which is gene in lettuce chloroplasts [43].

MAIZE:



Zea mays, commonly known as maize (/meɪz/) in North American and Australian English, is a tall, robust grass that yields cereal grains. About 9,000 years ago, indigenous peoples in southern Mexico tamed wild teosinte. It was grown by Native Americans in the Three Sisters polyculture with beans and squashes. The plant's leafy stalk gives rise to female inflorescences called ears that generate grain, often

referred to as kernels or seeds, and male inflorescences called tassels, which create pollen. These are often yellow or white in modern versions, though they can come in a variety of colours.

A variety of esculent vaccines have also been delivered using sludge as a vector. In order to develop a protein called HbsAg, which triggers a vulnerable reaction to hepatitis B contagion and may be employed as a vaccine, Egyptian scientists genetically modified sludge shops. More than 2 billion individuals with hepatitis B, 350 million of whom are at high risk of fatalities and serious illness from complications such as liver damage and liver cancer, will benefit if fatal trials are successful. Iowa State University is conducting research to enable humans and animals to receive a flu vaccination by merely consuming corn or corn-derived products. The possibility exists that the human corn vaccine would be effective if people consumed corn or anything made from corn, such as tortillas, corn flakes, or corn chips.

Transgenic sludge expressing the Vnukovo strain's the glycoprotein (G) was also generated by combining a native CaMV protagonist with a ubiquitin sludge protagonist coupled to the entire coding area of the rabies contagion gene. Using the above design, biolistic modified maize embryogenic callus. Plants of regenerated maize were collected and grown in a greenhouse. G-protein in grains accounted for around 1% of total soluble plant protein.

Given that the majority of corn-derived antigens are both immunogenic and antigenic, it is evident that most of them are correctly expressed. Transgenic material was generally used in the listed publications to elicit considerable selective IgG and IgA reactions (both local and systemic); nonetheless, it would be interesting to better characterize their capacity to trigger cellular immune responses in future investigations. Few studies have examined the immunoprotective potential of corn-based vaccines through experimental challenge with the matching pathogen; therefore, further study in this area is still needed [44].

One benefit of administering vaccinations orally via plant cells or biomass is that the plant chemicals can contribute to vaccine responsiveness through a variety of methods. Interestingly, one of the key plant proteins being researched for a range of biomedical applications, including oral administration of peptides and proteins, as well as vaccine delivery, DNA transmission, and the engineering of tissues, is zein, a significant protein spare in maize endosperm [45,46]. In order to mitigate biosafety risks associated with the utilization of open pollination species, large-scale manufacturing of vaccines based on maize might be carried out in greenhouses, which could offer ideal growth environment (Keese 2008) [47]. When it comes to yields, appropriate protein processing, and adaptability for industrial utilization, corn makes an appealing substrate for the antigen expression [48,49]. A strong potential for this technique was found in the preclinical study of numerous vaccines derived from maize that target human diseases. One candidate underwent review in a phase I clinical trial with encouraging outcomes [44].

As a comestible vaccination for people and animals, transgenic sludge (*Zea mays*) shops expressing rabies contagion antigenic glycoproteins demonstrated.

Carrot:



The carrot (*Daucus carota* subsp. *sativus*) is a root vegetable that is commonly orange in colour, however there are heirloom cultivars that are purple, black, red, white, and yellow as well. Each of the aforementioned cultivars are domesticated versions of the wild *Daucus carota*, which is native to Southwestern Asia and Europe. The species of plant was first cultivated for its leaves and seeds, and it most likely originated in Persia. While the stems and leaves are also consumed, the taproot is the portion of the plant that is most frequently consumed. The cultivated carrot's larger, more appetizing, and less woody-textured taproot is the result of careful breeding.

The Apiaceae family of umbellifers includes the biennial carrot plant. It develops a rosette of leaves at birth while it grows the larger taproot.

Genetically modified (*Daucus carota*) that contain the B component of the *Escherichia coli* thermolabile toxin stimulated IgA and IgG formation at both the intestinal and systemic levels in rats [50]. In addition to *A. thaliana*, carrots were used in investigational consumable vaccines for surface HIV antigen expression. Rat experiments revealed that treated animals had more benefits than non-treated animals [51]. Considering carrots are delicious and healthful, but also for the reason eating carrot-derived carotenoids makes rats' immune systems stronger—including their lymphocytes and monocytes—the use of carrots as a treatment for HIV appears promising [52]. It may therefore be advantageous for those with compromised immune systems to ingest this possibly edible anti-HIV vaccination. The promise of these vaccinations has to be confirmed by human studies.

Spinach:



Spinacia oleracea, or spinach, is a leafy green flowering plant native to Central and Western Asia. It is a member of the *Amaranthaceae* family, specifically the *Chenopodioideae* subfamily within the *Caryophyllales* order. Its leaves are a popular culinary vegetable that can be eaten fresh or preserved by freezing, canning, or dehydrating. It tastes significantly different when eaten raw or cooked, and steaming can reduce its high oxalate level.

The development of an edible vaccination has also been contemplated with regard to genetically engineered spinach. Research is being done on spinach as a plant-based, edible delivery system for the anthrax vaccine and for the HIV-1 Tat protein, which is a potential vaccine candidate. In one trial, the maturity of the receptor-binding sphere of the tobacco mosaic contagion was represented by a scrap of defensive antigen (PA), which was generated as a translational emulsion with a capsid protein on the external face of the contagion. The resulting recombinant virus was then injected into spinach. In lab animals, the PA expressed by plants is highly immunogenic.

Another vegetable that has been prioritized for edible vaccine manufacturing is spinach, a green leafy plant that is boosted by iron. Choosing spinach has the benefit of being able to be consumed both raw

and cooked. There are now ongoing efforts to create vaccinations against HIV infection using traditional methods.

Leafy green vegetable spinach (*Spinacia oleracea* L.) is high in nutrients. According to Roberts and Moreau (2016), it has at least 13 distinct flavonoids that have anticancer and antioxidant properties. Vitamin K and carotenoids, which are found in spinach (Bunea et al., 2008), are beneficial for protecting bone and heart health as well as eye conditions such cataracts and age-related macular degeneration. Furthermore, it lessens the detrimental effects of aging and shields the brain from oxidative stress, both of which accelerate the deterioration of brain function. Spinach may help prevent Alzheimer's disease, according to Jiraungkoorskul. One of the most important and nutrient-dense foods is spinach, which is low in calories and high in vitamins.


Soybean:



Native to East Asia, the soybean, frequently known as the soy bean or soya bean (*Glycine maximum*) is a type of legume that's extensively cultivated for its protean comestible bean. Soy milk is a traditional source of soybeans for unfermented foods, similar as tofu and tofu skin. Foods made from fermented soy include tempeh, nattō, instigated bean paste, and soy sauce. For numerous packaged refectation and beast feeds, defatted soybean mess is an important and cost-effective means of obtaining protein. For case, textured vegetable protein (TVP) and other soybean derivations are factors of multitudinous dairy and meat druthers.

Significant attention of nutritive minerals, B vitamins, and phytic acid can be set up in soybeans. Another derivate of recycling the soybean crop is soy vegetable oil painting, which finds use in both artificial and food operations. The current invention deals with vaccinations produced from transgenic soybeans that are intended for use in faves, wildlife, humans, and important agrarian creatures. These vaccinations are used to cover against cancer antigens, poisons, autologous or tone- proteins, as well as conditions linked to contagions, bacteria, fungi, spongers, or prion infections. The transgenic soybeans of the present invention can also be employed to induce forbearance to autoimmune antigens or forbearance to allergens, in cases where a person has acquired autoimmunity to tone or autologous proteins, independently, or exhibits acuity to the allergen in question. preventative treatment of individualities and/ or communities before they manifest perceptivity to allergens is another aspect of the invention. fresh features of the invention include the expression of protein adjuvants in transgenic soybeans and the use of the soybeans as an oral contraceptive. In the present work, the B- subunit of the thermolabile poison from *E.coli* bacteria were expressed in the soybean (*Glycine maximum*) endoplasmic reticulum (ER), producing a total antigen position of over to 2.4 percent of the total soybean

seed protein after drying for farther processing without any issues. also, systemic IgG and IgA situations rise in rats given this protein orally [35,53,54].



Alfalfa:



Alfalfa, often known as lucerne, is a perennial flowering plant belonging to the Fabaceae family of legumes. It is also known as *Medicago sativa*. It is grown as a significant fodder crop in numerous nations worldwide. It is utilized as a cover crop, green manure, and for hay, silage, and grazing. In North America, alfalfa is a common name. Australia, New Zealand, South Africa, and the United Kingdom are the countries where the name lucerne is most frequently used. On the surface, the plant looks a lot like clover, a cousin in the same family, especially when it's young with its trifoliate leaves, which are mostly rounded leaflets. The leaflets lengthen as the plant ages.

sprouts can be eaten raw, and vaccines made from seeds are stable for extended periods of time. The first evidence that lengthy protein chains can be correctly produced in the form of uncooked extracts when adequate plant components are employed was provided in 1999 by the effective oral immunization against virulent foot-and-mouth disease (FMDV) in rats [7,55] An edible vaccine was developed for use in veterinary settings using transgenic alfalfa (*Medicago sativa*) that expressed the antigen eBRV4 from swine rotavirus (BVR) VP4 [56]. In 2005, the hog pest virus glycoprotein E2 was expressed in transgenic alfalfa plants. It was reported in 2009 that transgenic alfalfa had been developed, expressing the C protein from the capsid virus that infects chickens. Other plants, such as *A. thaliana*, have generated the same antigen [57,58]. *Echinococcus granulosus* Eeg95-EgA31 was expressed in another alfalfa investigation. This plant has enormous potential for use in veterinary medicine, as demonstrated by the fact that the protein was isolated and transmitted straight from the leaves to the target organism [59].

The Alfa alfa plant was utilized to express Eeg95-EgA31 of *Echinococcus granulosus* and is used mostly for veterinary reasons in the development of edible vaccines [55].

Papaya:

Papaya, also known as *Carica papaya*, is the delicious fruit of a huge plant in the Caricaceae family. The papaya may be the result of the hybridization of two or more native *Carica* species from Mexico and Central America, despite its origins being somewhat mysterious. It is now grown in all of the tropical regions of the world as well as the warmest subtropical regions. The fruit of the papaya tree is mildly sweet and has a pleasant musky flavour that varies depending on the variety and region. In addition to being a common fruit for breakfast in many nations, it can also be found in pies, salads, sherbets, juices, and confections. You can boil the immature fruit like squash.

Using 19 transgenic papaya clones to express synthetic peptides, a papaya (*Carica papaya*) has been created around 2007 to prevent *Taenia solium*-caused cysticercosis. A 90% immunogenic response was seen in vaccinated rats during the vaccine's testing in these animals. Although pigs and humans are the two main carriers of the disease, these consumable vaccinations may provide good alleviation for both [60,61,62].

Quinoa:

Quinoa, also known as *Chenopodium quinoa* (/ˈkiːn.wɑː, kiˈnoʊ.ə/), is a plant with flowers in the family amaranth, whose origins are from Quechua kinwa or kinuwa. It is an annual perennial herbaceous plant grown mostly for its edible seeds, which possess greater quantities of protein, nutritional fiber, B complex vitamins, and minerals than the majority of cereal grains. Quinoa originates in the Andean area of northwest South America and is a pseudocereal that is botanically related to spinach and amaranth (*Amaranthus* spp.). Quinoa is not a grass. In the Lake Titicaca area of Peru and Bolivia, it was first utilized 5,200–7,000 years ago as animal feed and 3,000–4,000 years ago for human use.

Enzymatic bursa virus VP2 antigen expression in quinoa (*Chenopodium quinoa*) led to the development of an edible vaccine in 2012. With poultry veterinary medicine in mind, the vaccine was created [63,64,65].

Algae:

A combination of cholera toxin B and a virus causing foot and mouth disease produced the first edible vaccine based on algae [66]. The transgenic chloroplast of *C. reinhardtii* was employed in their investigation to express the vaccine. Despite the low levels of antigen expression, it was a historic moment for microalgal biotechnology. In a different work, biolistic bombardment was used to introduce E2, a structural protein of the Classical Swine Fever Virus (CFSV), into the chloroplast of *C. reinhardtii*. Despite the expression of antigens in chloroplasts, following oral immunization, no immune response was seen [67].

Over 30,000 different species of algae exist, however only a small number of microalgae have undergone genetic transformation to date because of certain cell components. *Arthrospira platensis* Gomont 1892, for example, has several strong endonucleases in its cytoplasm, which renders them ineffective for successful transformation [68]. Nonetheless, *gfp:gus* and hygromycin resistance genes were successfully incorporated within the genetic code of this blue green algae using *Agrobacterium*-based transformation, and in the near future, this technology may be used to create edible vaccines [69]. *Arthrospira platensis* has been shown to have potential activity against encased RNA viruses and may be used to develop a vaccine contrary to the novel Coronavirus disease (COVID-19), the deadliest global epidemic is brought on by the SARS-CoV-2 virus [70]. This discovery was made after a thorough review of the literature. Investigators at the University of California successfully produced the spike protein Receptor Binding Domain (RBD) of *C. reinhardtii*, which provides insight for the scientific community in developing an affordable coronavirus vaccine [71].

Green algae, *Chlamydomonas reinhardtii*, was successfully used to manufacture a vast array of animal and human-specific proteins for medical applications [35,48]. Algae grow so quickly that the entire system can be utilized as a raw material to make vaccines that can be eaten. Additionally, algae that are growing swiftly can be developed in bioreactors. *C. reinhardtii* has a single chloroplast, which contributes to the preservation of the target antigens within the cell line. Notably, lyophilization has no effect on the effectiveness of algal vaccines, indicating that the delivery of edible algae vaccines could be made easier on a global scale.

Merits of edible vaccines:

- Edible vaccines tend to be successful for immunization delivery vehicles because they do not require adjuvants to increase the body's response to infection.
- Edible vaccines can induce mucosal immunity, which does not occur with standard vaccines [72].
- In contrast to standard immunizations, edible vaccines are subunit formulations, do not contain attenuated pathogens. This increases individual safety by eliminating the possibility of proteins reverting to infectious organisms.
- It is quite simple to separate and purify vaccines from plant components, and it is possible to successfully prevent pathogenic contamination from animal cells.
- Unlike standard vaccines, which must be administered by injection, edible vaccines are easily tolerated.
- There is less need for medical staff and little chance of contamination. Another benefit is that oral delivery is more feasible than injection.
- Due to their low cost, they may be made in huge quantities.

- the separation and sanctification of vaccines from factory accoutrements is veritably easy and pathogenic impurity from beast cells can be effectively averted.

Disadvantages of edible vaccine:

- A person may grow immunological resistant to the specific protein or peptide used in the vaccination.
- The necessary dosage changes with each generation and plant, depending on factors including the protein content, patient age, weight, fruit ripeness, and amount consumed.
- Methods for standardizing plant material or product are necessary for the administration of edible vaccines because high dosages are what induce immunological tolerance while smaller doses may result in fewer antibodies.
- Because some foods, like potatoes, must be cooked in order to denaturate or reduce their protein content, edible vaccinations depend on plant stability [73].
- Microbial infestation is a common problem with edible vaccines. For example, potatoes with vaccine can remain viable for a long time if refrigerated at 4°C, but tomatoes cannot [74].
- A clear demarcation line between "vaccine fruit" and "normal fruit" is required to prevent vaccine misadministration, which can result in vaccine tolerance.
- There is a significant difference in the glycosylation patterns of plants and humans, which may reduce the efficacy of edible vaccines.

References

1. Stern A.M., Markel H., "The history of vaccines and immunization: Familiar patterns, new challenges". *Health Affairs*. 2005,24(3),611–621.
2. Zeitlin L., Cone R.A., Whaley K.J., "Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases". *Emerg Infect Diseses* Jan-Feb 1999,5(1), 54–64.
3. Arntzen C.J., "Edible vaccines". *Public Health Report* May-Jun 1997,112(3),190-197. PMID: 9182305.
4. Ankita M., Sachin M.V., Mohana S., Subathra Devi C., "Banana as Edible Vaccine Against Hepatitis-B: A Theoretical Model" *Bentham Science*,2016, 16(2),129-133.
5. Jyoti S., Shweta R., "Advances in Biotechnology" 22 Oct 2013,
6. Walmsley A.M., Arntzen C.J., "Plant cell factories and mucosal vaccine", *Curr Opin Biotechnology*, 2003 Apr;14(2):145-50.
7. Concha C., Cañas R., Macuer J., et al. "Disease prevention: An opportunity to expand edible plant-based vaccines". *Vaccine*. 2017;5(2):14–23.
8. Arakawa T., Chong D.K., Merritt J.L., Langridge W.H., "Expression of cholera toxin B subunit oligomers in transgenic potato plants". *Transgenic Res* 1997; 6: 403–413.
9. Mason HS. "Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice". *Proceedings of the National Academy of Sciences USA*. 1996,93,5335–5340.
10. Oszvald M., Kang T.J., Tomoskozi S., Tamas C., Tamas L., Kim T.G., Yang M.S., "Expression of a synthetic neutralizing epitope of porcine epidemic diarrhea virus fused with synthetic B subunit of Escherichia coli heat labile enterotoxin in rice endosperm", *Mol Biotechnology*, March 2007,35(3),215-23. doi: 10.1007/BF02686007. PMID: 17652785.

11. Chowdhury K., Bagasra O., “An edible vaccine for malaria using transgenic tomatoes of varying sizes, shapes and colors to carry different antigens”. *Med Hypotheses*. 2007;68(1):22-30. doi: 10.1016/j.mehy.2006.04.079. Epub 2006 Oct 2. PMID: 17014967.
12. Okie S., “Betting on malaria vaccine”, *New England J Med*, Nov 2005,353, 1877-1881
13. J.P. Boutin *et al.*, *Epidemiology of malaria, Pathogenesis, clinical features, and neurological outcome of cerebral malaria*, *Rev Prat*, 2005.
14. R. Idro *et al.*, “*Lancet Neurol*”, 2005.
15. E. Worrall *et al.*, “Is malaria a disease of poverty? A review”, *Trop Med Int Health*, 2005.
16. M.T. Duraisingh *et al.*, “Multiple drug resistance genes in malaria – from epistasis to epidemiology” *Mol. Microbiology*, 2005.
17. Doshi V., Rawal H., Mukherjee S., “Edible vaccines from GM crops: current status and future scope”, *J Pharma Sci Innovat Jun 2013*, 2(3),1–6.
18. Zhang X., Buehner N.A., Hutson A.M., et al., “Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein”, *Plant Biotechnology Journal*, Nov 2006, 4, 419–432
19. Marshall B.J., Warren J.R., “Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration”, *Lancet*, Jun 1984 16(1),1311-1515
20. Parsonnet J., Friedman G.D., Vandersteen D.P., Chang Y., Vogelmann J.H., Orentreich N., Sibley R.K., “*Helicobacter pylori* infection and the risk of gastric carcinoma”. *N Engl J Med*. Oct 1991,325(16),1127-1131.
21. Sidebotham R.L., Baron J.H., “Hypothesis: *Helicobacter pylori*, urease, mucus, and gastric ulcer”, *Lancet*, 27 Jan 1990,335(8683),193-5.
22. Fujii R., Morihara F., Fukushima K., Oku T., Hifumi E., Uda T., “Recombinant antigen from *Helicobacter pylori* urease as vaccine against *H. pylori*-associated disease”, *Biotechnology Bioengineering*, 30 Jun 2004, 86(7),737-746.
23. Yang X.L., Liu W.C., Yang W.W., Zhong D., Liu Y.H., Zhang J.D., Jiang J.H., Li S.S., “Oral immunization of mice with vaccine of attenuated *Salmonella typhimurium* expressing *Helicobacter pylori* urease B subunit”, *Biomed Environ Science Dec 2005*,18(6),411-8.
24. Gu Q., Han N., Liu J et al., “Expression of *Helicobacter pylori* urease subunit B gene in transgenic rice”. *Biotechnology Letter*, Aug 2006, 28,1661–1666.
25. Azegami, T., Itoh H., Kiyono H. et al., “Novel Transgenic Rice-Based Vaccines” *Arch. Immunol. Ther. Exp.*, July 2016, 63, 87–99.
26. Matsumoto Y., Suzuki S., Nozoye T., Yamakawa T., Takashima Y., Arakawa T., Tsuji N., Takaiwa F., Hayashi Y., “Oral immunogenicity and protective efficacy in mice of transgenic rice plants producing a vaccine candidate antigen (As16) of *Ascaris suum* fused with cholera toxin B subunit”, *Transgenic Research*, April 2009,18(2),185-92.
27. Guerrant R.L., Brunton L.L., Schnaitman T.C., Rebhun L.I., Gilman A.G., “Cyclic adenosine monophosphate and alteration of Chinese hamster ovary cell morphology: a rapid, sensitive in vitro assay for the enterotoxins of *Vibrio cholerae* and *Escherichia coli*”, *Infect Immunology*, August 1974,10(2),320-327.
28. Svennerholm A.M., Holmgren J., “Identification of *Escherichia coli* heat-labile enterotoxin by means of a ganglioside immunosorbent assay (Gm1-Elisa) procedure”, *Curr Microbiol*, January 1978,1,19–23

29. Koya V., Moayeri M., Leppla S.H., Daniell H., “Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge”, *Infect Immunology*, December 2005, 73(12), 8266–8274.
30. Kishore K., (2014). “Monograph of tobacco (*Nicotiana tabacum*)”, *Indian Journal of Drugs*, March 2014,2(21), 5–23.
31. Ilana, B., Torres, E. G., Walt, H., Wolf, U., Maake, C, Martin-Soelch C., “Tobacco is the chief medicinal plant in my work: Therapeutic uses of tobacco in Peruvian Amazonian medicine exemplified by the work of a maestro Tabaquero”, *Frontiers in Pharmacology*, October 2020, Vol.11.
32. Tobacco. (2021). WHO statistics. Retrieved from <https://www.who.int/news-room/factsheets/detail/tobacco>.
33. Laere E., Ling A. P. K., Wong Y. P., Koh R. Y., Lila M. A. M., Hussein S., “Plant-based vaccines: Production and challenges”, *Journal of Botany*, April 2016, Vol 2016, 1–11.
34. Kurup V.M., Thomas J., “Edible Vaccines: Promises and Challenges”, *Molecular Biotechnology* February 2020, 62(2),79-90.
35. Saxena J., Rawat S., “Edible Vaccines”, *Advances in Biotechnology*. Oct 2013, 22:207–26.
36. Dubey K.K., Luke G.A., Knox C., Kumar P., Pletschke B.I., Singh P.K., Shukla P., “Vaccine and antibody production in plants: developments and computational tools”, *Brief Funct. Genomics*, September 2018,17(5),295-307.
37. Pang T., Mak T.K., Gubler D.J., “Prevention and control of dengue-the light at the end of the tunnel”, *Lancet Infect Dis*. March 2017,17(3),79-87.
38. FDA. (2021). DENG VAXIA | FDA. Retrieved from <https://www.fda.gov/vaccines-blood-biologics/dengvaxia>.
39. Mathew M., Thomas J., “Tobacco-Based Vaccines, Hopes, and Concerns: A Systematic Review”, *Molecular Biotechnology*, July 2023, 65, 1023–105.
40. Kim M.Y., Yang M.S., Kim T.G., “Expression of dengue virus E glycoprotein domain III in non-nicotine transgenic tobacco plants”, *Biotechnology and Bioprocess Engineering*, December 2009, 14(6), 725–730.
41. Ponndorf D., Meshcheriakova Y., Thuenemann E.C., Dobon Alonso A., Overman R., Holton N., Dowall S., Kennedy E., Stocks M., Lomonosoff G.P., Peyret H., “Plant-made dengue virus-like particles produced by co-expression of structural and non-structural proteins induce a humoral immune response in mice”, *Plant Biotechnol Journal*, April 2021,19(4),745-756.
42. Saejung W., Fujiyama K., Takasaki T., Ito M., Hori K., Malasit P., Watanabe Y., Kurane I., Seki T., “Production of dengue 2 envelope domain III in plant using TMV-based vector system” *Vaccine*, September 2007,25(36),6646-54.
43. Ahmed A.S., Kadhim M.I., Abdulwahid A.I., “Production of Lettuce Edible Vaccine for Cholera Disease Using Chloroplast Genetic Engineering”, *Journal of university of Anbar for pure science*, April 2013, 7(1).
44. Rosales-Mendoza S., Sáñez-Robledo C., Bañuelos-Hernández B. et al., “Corn-based vaccines: current status and prospects”, *Planta* 245, May 2017, 875–888.
45. Hurtado-López P., Murdan S., “Zein microspheres as drug/antigen carriers: a study of their degradation and erosion, in the presence and absence of enzymes”, *J Microencapsul*, May 2006,23(3),303-314.

46. Muthuselvi L., Dhathathreyan A., “Simple coacervates of zein to encapsulate Gitoxin”, *Colloids Surf B Biointerfaces*, August 2006,51(1),39-43.
47. Keese P., “Risks from GMOs due to horizontal gene transfer”, *Environ Biosafety Research*, Jul-Sep 2008,7(3),123-49.
48. Aswathi P.B., Bhanja S.K., Yadav A.S., Rekha V., John J.K., Gopinath D., Sadanandan G.V., Shinde A., Jacob A., “Plant Based Edible Vaccines against Poultry Diseases: A Review” *Adv. Anim. Vet. Sci.* 2014, 2(5), 305–311.
49. Thanavala Y., Lugade A.A., “Oral transgenic plant-based vaccine for hepatitis B”, *Immunology Research*, March 2010,46(1-3),4-11.
50. Rosales-Mendoza S., Alpuche-Solís A., Soria-Guerra R., Moreno-Fierros L., Martínez-González L., Herrera-Díaz A., Korban S.S., “Expression of an Escherichia coli antigenic fusion protein comprising the heat labile toxin B subunit and the heat stable toxin and its assembly as a functional oligomer in transplastomic tobacco plants”, *Plant J.* December 2008, 57(1), 45–54.
51. Lindh I., Brave A., Hallengard D., Hadad R., Kalbina I., Strid A., Andersson S., “Oral delivery of plant-derived HIV-1 p24 antigen in low doses shows a superior priming effect in mice compared to high doses Ingrid” *Vaccine* 2014, 32, 2288–2293.
52. Ekam V.S., Udosen E.O., Chigbu A.E., “Comparative effect of carotenoid complex from Golden Neo-Life Dynamite (GNLD) and carrot extracted carotenoids on immune parameters in albino Wistar rats”, *Niger Journal of Physiology Science*, Jun-Dec 2006,21(1-2),1-4.
53. Takagi H., Hiroi T., Yang L., Tada Y., Yuki Y., Takamura K., et al. “A rice-based edible vaccine expressing multiple T cell epitopes induces oral tolerance for inhibition of Th2-mediated IgE responses”, *Proc Natl Acad Sci USA*, 2005,102(48),17525-17530.
54. Patel P., Patel R., Patel S., Patel Y., Patel M., Trivedi R., “Edible Vaccines: A Nutritional Substitute for Traditional Immunization”, *Pharmacog Reviews*, August 2022,16(32),62-69.
55. Wigdorovitz A., Pérez Filgueira D.M., Robertson N., Carrillo C., Sadir A.M., Morris T.J., Borca M.V., “Protection of mice against challenge with foot and mouth disease virus (FMDV) by immunization with foliar extracts from plants infected with recombinant tobacco mosaic expressing the FMDV structural protein VP1”, *Virology*, 1999,264,85-91.
56. Wigdorovitz A., Mozovoj M., Santos M., Parreno V., Gomez C., PerezFilgueira D.M., Trono K.G., Ríos R.D., Franzone P.M., Fernández F, et al, "Protective lactogenic immunity conferred by an edible peptide vaccine to bovine rotavirus produced in transgenic plants", *J. Gen. Virology*, 2004; 85:1825-1832.
57. Wu J., Yu L., Li L., Hu J., Zhou J., Zhou X., “Oral immunization with transgenic rice seeds expressing VP2 protein of infectious bursal disease virus induces protective immune responses in chickens”, *Plant Biotechnology Journal*, June 2007, 5(5), 570–578.
58. Huang L.K., Liao S.C., Chang C.C., Liu H.J., “Expression of avian reovirus sigmaC protein in transgenic plants”, *J Virol Methods*, June 2006, 134(1-2),217-22.
59. Yan-Ju Y.E., Wen-Gui L.I., "Immunoprotection of transgenic alfalfa (*Medicago sativa*) containing Eg95-EgA31 fusion gene of *Echinococcus granulosus* against *Eg* protozoa", *J. Trop. Med.* 2010, 5(2), 10–13.
60. Sciutto E., et al. “New approaches to improve a peptide vaccine against porcine *Taenia solium* cysticercosis”, *Archives of Medical Research*, July 2002,33(4),371-378.

61. Sciutto E., et al., “Towards a practical and affordable oral papaya-based vaccine: a crucial tool for taeniasis cysticercosis control programs”, *Bioprocess Sciences and Technology*, 2011.
62. Rosales S., et al. “Toward a papaya-based oral vaccine against cysticercosis”, *Acta Hort.* 2019 doi: 10.17660/ActaHortic.2019.1250.30.
63. Chen T.H., Chen T.H., Hu C.C., Liao J.T., Lee C.W., Liao J.W., Lin M.Y., Liu H.J., Wang M.Y., Lin N.S., Hsu Y.H., “Induction of protective immunity in chickens immunized with plant-made chimeric Bamboo mosaic virus particles expressing very virulent Infectious bursal disease virus antigen”, *Virus Research*, June 2012,166(1-2),109-15.
64. Hilleman MR. “Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine”, 2000 Feb 14,18(15),1436-47.
65. Kumar G.B., Ganapathi T.R., Revathi C.J., Srinivas L., Bapat V.A., "Expression of hepatitis B surface antigen in transgenic banana plants", *Planta*, 2005, 222,484-493.
66. Sun M., Qian K., Su N., Chang H., Liu J., Shen G., “Foot-and-mouth disease virus VP1 protein fused with cholera toxin B subunit expressed in *Chlamydomonas reinhardtii* chloroplast”, *Biotechnology Letter*, July 2003, 25(13),1087-92.
67. He D.M., Qian K.X., Shen G.F., Zhang Z.F., Li Y.N., Su Z.L., Shao H.B., “Recombination and expression of classical swine fever virus (CSFV) structural protein E2 gene in *Chlamydomonas reinhardtii* chloroplasts”, *Colloids Surf B Biointerfaces*, March 2007,15,55(1),26-30.
68. Shiraishi H., Tabuse Y., “The *AplII* restriction-modification system in an edible cyanobacterium, *Arthrospira (Spirulina) platensis* NIES-39, recognizes the nucleotide sequence 5'-CTGCAG-3'. *Biosci Biotechnol Biochemistry*”, 2013,77(4),782-8.
69. Dehghani J., Adibkia K., Movafeghi A. et al., “Stable transformation of *Spirulina (Arthrospira) platensis*: a promising microalga for production of edible vaccines”, *Appl Microbiol Biotechnol*, 2018,102,9267–9278.
70. Elaya Perumal U., Sundararaj R., “Algae: a potential source to prevent and cure the novel coronavirus – a review”, *Int J Emerg Technol*, April 2020,11(2),479–483.
71. Jiji M.G., Ninan M.A., Thomas V.P., Thomas B.T., “Edible microalgae: potential candidate for developing edible vaccines”, *Vegetos*, Apr 2023,1-6.
72. Bhatia S., Dahiya R., “Edible Vaccines. Modern Applications of Plant Biotechnology in Pharmaceutical Sciences”, Elsevier PMC COVID-19 Collection, July 2015,333–343.
73. Moss W.J., Cutts F., Griffin D.E., “Implications of the human immunodeficiency virus epidemic for control and eradication of measles”, *Clin Infect Diseases*, July1999,29(1),106-12.
74. Jan N., Shafi F., Hameed O., Muzaffar K., Dar S.M., Majid I. et al. “An Overview on Edible Vaccines and Immunization”, *Austin J Nutri Food Science*, June 2016,4(2),1078.